Investors to Hear Directly From Companies Including Beckman Coulter, Nektar Therapeutics and BioMarin Pharmaceutical at Biotechnology & Healthcare Stocks Forum in Foster City, CA on Dec. 7
SCOLR, Genetronics Biomedical, and Lorus Therapeutics also to present with John McCamant, Editor of The Medical Technology Stock Letter, Delivering the Keynote
San Francisco, CA – November 18, 2004 – Investors interested in Biotechnology and Healthcare stocks will receive the latest updates at the Informed Investors Forum on December 7. The analyst-style forum, which includes presentations from top executives of Biotechnology and Healthcare firms, followed by question and answer sessions, will be held at The Crowne Plaza in Foster City, CA at 1221 Chess Dr. starting at 8:30 am PST. A webcast of the forum will be archived on www.informedinvestors.com following the event.
This live forum will include presentations by executives from SCOLR, Beckman Coulter, Gammacan International, Nektar Therapeutics, Genetronics Biomedical, Lorus Therapeutics, BioMarin Pharmaceutical and Aethlon Medical. John McCamant, Editor of The Medical Technology Stock Letter, will deliver the keynote address.
Beckman Coulter (NYSE: BEC) is a global biomedical company that develops and markets instruments, chemistries, software and supplies that simplify and automate laboratory processes throughout the biomedical-testing continuum.
Nektar Therapeutics (NasdaqNM: NKTR) provides a portfolio of leading drug delivery solutions that enable the development of high-value pharmaceutical products.
BioMarin Pharmaceutical (NasdaqNM: BMRN) is dedicated to developing innovative biopharmaceutical products and commercializing therapeutics for serious pediatric diseases.
SCOLR, Inc. (AMEX: DDD) is a specialty pharmaceutical company leveraging formulation expertise and its patented CDT® platform to introduce distinctive and novel OTC products, prescription drugs and dietary supplements.
Genetronics Biomedical (AMEX: GEB) specializes in developing technology and hardware, which potentially will allow physicians more efficiently and cost-effectively to deliver life-saving drugs or beneficial genes to patients with catastrophic illnesses, including cancer.
Gammacan International (OTC BB: GCAN) is a biopharmaceutical company focused on clinical-phase development and commercialization.
Lorus Therapeutics (LOR.TO) is focused on the discovery, research and development of novel, well-tolerated therapies that successfully manage cancer and promote improved quality of life.
Aethlon Medical (OTC BB: AEMD) is pioneering the development of viral filtration devices that rapidly reduce the presence of infectious disease and toxins in the body.
| Back to News | Back to Top |